Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 14/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 14/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765650 | 1.00 | TAS1R3 (0.50) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL4761901 | 0.93 | TAS1R3 (0.48) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL4761899 | 0.93 | TAS1R3 (0.48) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL6590279 | 0.92 | TAS1R3 (0.39) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL6590283 | 0.92 | TAS1R3 (0.39) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL4770836 | 0.91 | TAS1R3 (0.51) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL4770834 | 0.91 | TAS1R3 (0.51) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL6591709 | 0.90 | CTSK (0.46) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL6591711 | 0.90 | CTSK (0.46) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL4762072 | 0.88 | TAS1R3 (0.49) | TAS1R3TAS1R1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |